Good
Mostly Aligned
Patient Risk:
Low
Summary
Most safety-related concepts in the supplied claims (e.g., cardiovascular disorders, probable dementia, breast cancer, endometrial cancer/endometrial cancer risk with unopposed estrogen) are consistent with the provided Angeliq label excerpts. However, several claims are general statements about switching/substitutes/patent resources that are not supported or only partially address label content, and the provided overall evidence block appears to ignore evaluating those specific claims against label text.
Category Scores
Accurate Statements
Angeliq increases risk of cardiovascular disorders (e.g., PE, DVT, stroke, MI).
Supported by Boxed Warning (Estrogen Plus Progestin Therapy; Cardiovascular Disorders and Probable Dementia) and Warnings and Precautions (5.1 Cardiovascular Disorders).
Angeliq increases risk of probable dementia.
Supported by Boxed Warning (Probable Dementia) and Warnings and Precautions (5.4 Probable Dementia).
Angeliq increases risk of breast cancer.
Supported by Boxed Warning (Breast Cancer) and Warnings and Precautions (5.3 Malignant Neoplasms: Breast Cancer).
There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens; adding a progestogen reduces risk of endometrial hyperplasia.
Supported by Boxed Warning (Estrogen-Alone Therapy: Endometrial Cancer) and Warnings and Precautions (5.3 Malignant Neoplasms: Endometrial Cancer).
Unsupported Statements
Whether a true generic version of Angeliq exists depends on each country's approvals and the specific product.
No information in the provided label excerpts addresses generic availability by country or product-level substitution.
The closest substitutes for Angeliq are other combination therapies that pair estradiol and drospirenone.
Label excerpts provided do not discuss substitutability, therapeutic alternatives, or criteria for 'closest substitutes.'
Estradiol-only drugs usually require a separate progestin for people who have a uterus.
The label excerpt provided states increased endometrial cancer risk with unopposed estrogen and that adding a progestogen reduces endometrial hyperplasia risk, but it does not state that estradiol-only drugs 'usually require' a separate progestin.
Patients and prescribers sometimes switch between other estradiol plus different progestin combinations (not drospirenone).
The provided label excerpts do not discuss switching behavior or common clinical practice.
Patients and prescribers sometimes switch between estradiol-only with an added progestin taken separately.
The provided label excerpts do not discuss switching patterns or separate progestin administration as a common approach.
Switching hormone therapy should be done with a clinician's guidance.
The provided label excerpt includes re-evaluation and guidance on using lowest effective dose/shortest duration, but it does not explicitly state a recommendation about switching with clinician guidance.
Small differences in dose, formulation, and progestin type can affect side effects such as breast tenderness or breakthrough bleeding.
The provided label excerpts do not discuss dose/formulation/progestin-type effects on specific side effects like breast tenderness or breakthrough bleeding.
Small differences in dose, formulation, and progestin type can matter for safety.
The label excerpts provided do not support this generalized statement in the way it is phrased (no direct claim about safety differences by formulation/dose/progestin type).
Differences in bleeding patterns and risk profile can differ between an Angeliq 'similar' replacement and other options.
No provided label excerpts discuss 'similar' replacement products, bleeding pattern comparisons between alternatives, or comparative risk profiles.
DrugPatentWatch.com can be a useful starting point for checking patent status related to Angeliq's key actives and formulations.
No label content references DrugPatentWatch.com or patent-status resources.
Contradictions
Important Omissions
For the safety topics that are referenced (cardiovascular disorders, probable dementia, breast cancer, endometrial cancer), the label excerpts emphasize that these findings come from WHI/WHIMS studies with specific regimens and include specific instructions such as 'Do not use... for the prevention of cardiovascular disease or dementia' and 'Prescribe at the lowest effective doses and for the shortest duration.'
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only label-aligned content in the supplied evaluation pertains to boxed-warning level risks (cardiovascular disorders, probable dementia, breast cancer, endometrial cancer risk with unopposed estrogen). However, several other claims are generic/unsourced with respect to the provided label excerpts, which reduces on-label alignment for the full set of statements.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Multiple claims about generics/substitutes, switching, formulation/dose differences affecting specific side effects, and a patent-checking website are not supported by the provided Angeliq prescribing information excerpts.
Suggested Improvement
Restrict statements to what is explicitly covered in the label excerpts (boxed warning and Warnings/Precautions sections) or clearly qualify/omit claims not addressed in the label (e.g., generic availability, switching frequency, specific side effects like breakthrough bleeding, and external resources). Include label-specific instructions such as 'Do not use... for prevention of cardiovascular disease or dementia' and 'lowest effective dose/shortest duration' when discussing these risks.